# A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

> **NCT03239340** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 154 (actual)

## Conditions studied

- EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03239340
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2023-09-19
- **Final completion:** 2023-09-19
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03239340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03239340, "A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03239340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*